CERO THERAPEUTICS HOLDINGS, INC. (CERO): Nasdaq/NYSE listing notice — CERo Therapeutics receives Nasdaq bid price deficiency notice; effects 1-for-20 reverse split

CERO THERAPEUTICS HOLDINGS, INC.

Received Nasdaq notice on June 11, 2025: bid price below $1.00 for 30 consecutive business days (Apr 25–Jun 9).
Not eligible for standard compliance period due to prior reverse stock splits; plans to request a hearing.
Effected 1-for-20 reverse stock split on June 13, 2025; closing bid price was $7.31.
No assurance that bid price will remain above $1.00 or that hearing will grant continued listing.
Common stock (CERO) and warrants (CEROW) continue trading on Nasdaq pending hearing outcome.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 11, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter (the “Bid Price Requirement Letter”) from the Listing Qualifications Department (the “Staff”) at The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business day period between April 25, 2025 through June 9, 2025, the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-054371

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.